Research Grant: Endometrial Cancer (Dostarlimab)

Investigation of dostarlimab in Gyn-Onc, Head and Neck, and Colorectal/GI indications that can support current registrational studies through meaningful evidence generation.
Endometrial Cancer
1.   Translational research on anti-PD-(L)1 resistance
2.   ctDNA clinical utility in EC and for IO monitoring
3.   IO combination approaches for IO-exposed EC
4.   IO combination approaches for MMRp/MSS EC
5.   IO for early-stage EC with EBRT sparing strategies

GI
1.   RWD with focus on complementing the AZUR-1 study of dostarlimab in dMMR/MSI-H LARC evaluating dostarlimab as a surgery sparing therapy compared to current SOC
2.   Investigate optimal duration of therapy with dostarlimab (i.e. retreatment, ctDNA guided approach, etc.)

Head and Neck
1.   Investigate novel combinations (e.g. B7H3)
2.   Optimal duration of treatment, IO after IO (retreatment?) sequencing: neoadjuvant, adjuvant, maintenance
3.   Exploration in settings outside of unresected, locally advanced population and beyond HNSCC (nasopharyngeal?)
4.   Exploration in advanced disease with potential for organ-sparing, de-escalation of treatment (including surgery and radiation)

Other
1.   Supporting organ sparing approaches using dostarlimab across other tumors.